At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Not Yet Opened 11-16 16:08:13
83.900
-0.850
-1.00%
High86.350
Low82.950
Vol13.36M
Open84.750
D1 Closing84.750
Amplitude4.01%
Mkt Cap146.66B
Tradable Cap146.66B
Total Shares1.75B
T/O1.13B
T/O Rate0.76%
Tradable Shares1.75B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Innovent Biologics Partner Ollin Biosciences and Its Next-Gen Eye Disease Pipeline to Be Acquired
Fortvita Receives Its First Positive Chmp Opinion, Recommending Zybrivo® (Sintilimab) for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer
Hong Kong Stock Concept Tracker: 51 Class 1 Innovative Drugs Added to Updated National Reimbursement Drug List, Commercialization of Innovative Drugs Accelerates (With Concept Stocks)
Several GLP-1 Injectables Enter National Basic Medical Insurance List for the First Time, Including Pfizer and Innovent Bio Products, for Treating Adults with Type 2 Diabetes
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.